Zanidatamab Plus Chemotherapy Prolongs PFS Over Trastuzumab Plus Chemotherapy in Patients with HER2-positive Advanced Gastro-Oesophageal Adenocarcinoma By Ogkologos - June 1, 2026 220 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HERIZON-GEA-01 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New hormone treatment for advanced prostate cancer made available in England June 8, 2021 Νέα για τον καρκίνο του προστάτη June 9, 2019 FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly with Chemotherapy September 5, 2024 Embrace Your Inner Flexibility March 29, 2021 Load more HOT NEWS Carvykti Approval Marks Second CAR T-Cell Therapy for Multiple Myeloma ESMO Congress 2022, 9-13 September Women Over Age 65 Years with Pathogenic Variants in Cancer Predisposition... Patient Guide in Prostate Cancer Now Available in Vietnamese
